Background {#Sec1}
==========

Dipeptidyl peptidase-4 inhibitors (DPP-4is) lower plasma glucose and glycated hemoglobin in people with type 2 diabetes by inhibiting degradation of endogenous glucagon-like peptide-1 (GLP-1) \[[@CR1]\]. They have a low risk for hypoglycemia and are weight neutral \[[@CR2]\]. Although two GLP-1 receptor agonists, once-daily liraglutide \[[@CR3]\] and once-weekly semaglutide \[[@CR4]\], have been shown to reduce cardiovascular (CV) events in patients with type 2 diabetes at high CV risk, four CV outcome trials that evaluated the once-daily DPP-4i agents saxagliptin \[[@CR5]\], alogliptin \[[@CR6]\], sitagliptin \[[@CR7], [@CR8]\], and linagliptin \[[@CR9], [@CR10]\] versus placebo showed no impact on CV death, myocardial infarction (MI), or stroke outcomes.

GLP-1 receptors are expressed on cells in CV tissues \[[@CR11]\], and multiple CV effects of GLP-1 receptor agonism have been demonstrated with administration of native GLP-1, with administration of GLP-1 receptor agonists, and with DPP-4i treatment in preclinical studies \[[@CR11]--[@CR14]\]. Among these well-documented effects is a substantial (30--50%) reduction in the extent of myocardial necrosis after experimentally induced MI in rodents pretreated with native GLP-1 \[[@CR15], [@CR16]\] or with a GLP-1 receptor agonist \[[@CR17], [@CR18]\]. Similar experimental approaches with a DPP-4i in mice \[[@CR19]\], rats \[[@CR20]\], pigs \[[@CR21]\], and dogs \[[@CR22]\] produced largely similar results. Regarding potential mechanisms, sitagliptin seems to improve tolerance to ischemia as demonstrated by an improved regional contractility in ischemic segments of the left ventricle \[[@CR23], [@CR24]\]. These effects of DPP-4 inhibition may be mediated by protection of mitochondrial function and preventing cardiomyocyte apoptosis, and by interfering with oxidative stress during reperfusion \[[@CR20], [@CR21]\]. Theoretically, a smaller infarct size in humans could result in lower incident case-fatality, less post-MI arrhythmogenic risk, and higher residual left-ventricular function with a lower future risk of heart failure or CV death \[[@CR25], [@CR26]\].

The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) randomized patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) to double-blind therapy with sitagliptin or placebo, in addition to usual care, aiming for glycemic equipoise \[[@CR7], [@CR8]\]. In a post hoc analysis, we evaluated the effects of sitagliptin on a composite outcome defined as CV death or hospitalization for heart failure (hHF) in TECOS participants who experienced a within-trial MI.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The TECOS design \[[@CR8]\] and primary results \[[@CR7]\] and heart failure outcomes \[[@CR27]\] have been published previously. Briefly, 14,671 participants from 38 countries were enrolled between December 2008 and July 2012. Eligible participants were ≥ 50 years old (no upper age limit) with type 2 diabetes, ASCVD, and glycated hemoglobin (HbA~1c~) values of 6.5--8.0% (48--64 mmol/mol) on stable dose mono- or dual-combination therapy with metformin, pioglitazone, sulfonylurea or insulin (with or without metformin). Participants were randomized double-blind to sitagliptin or placebo at doses appropriate for their eGFR \[[@CR7], [@CR8]\]. During follow-up, treatment for hyperglycemia and for type 2 diabetes comorbidities was provided by usual care providers according to their local guidelines with addition of any open-label glucose-lowering agent permitted, apart from a GLP-1 receptor agonist or DPP-4i. All reported events of death, MI, stroke, and hospitalization for unstable angina or heart failure were adjudicated by an independent committee masked to randomized treatment assignment. Adjudicated event definitions have been published previously \[[@CR7], [@CR8]\].

Objectives {#Sec4}
----------

The analyses presented here examine only those participants who experienced an MI during the trial. We evaluated potential differences between the randomized groups in case-fatality and for those with a non-fatal MI the time to a composite outcome defined as CV death or hHF. Secondary outcomes were post-MI time to CV death, hHF, and all-cause death. We also examined hHF in patients not known to have heart failure at baseline, and an extended composite outcome defined as CV death, hHF, a further MI, stroke, or new-onset atrial fibrillation.

Statistical analysis {#Sec5}
--------------------

Baseline characteristics for continuous variables were summarized as median and interquartile range (IQR), and categorical variables as count (percentage).

Primary analyses were performed on the intention-to-treat population in the subset who experienced an MI during the trial. Secondary on-treatment sensitivity analyses were performed with participants classified as "DPP-4i treated" if they were taking double-blind sitagliptin study medication or if they were taking an open-label DPP-4i. Similarly, they were classified as "not DPP-4i treated" if they were taking double-blind placebo study medication or had discontinued double-blind sitagliptin study medication and were not taking an open-label DPP-4i.

The two treatment groups were compared using Cox proportional hazards models, without and with adjustment for potential confounders. Adjustment factors applied were those previously identified in the large Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) clinical trial \[[@CR28], [@CR29]\]. The assumptions of linearity and proportional hazards had been previously evaluated for the set of confounders considered and appropriate adjustments applied when violations were noted. The list of covariates is provided in Additional file [1](#MOESM1){ref-type="media"}: Table S1. The proportional hazards assumption was tested for the treatment factor in these new models, and time-varying models would have been applied had violations been noted. Follow-up began (day 0) at the date of the first within-trial MI and continued until the date of the first occurrence of each type of endpoint considered here or the date of last contact when no event occurred. The analyses were performed twice in consideration of fatal MIs. In one case (primary analyses), only patients with nonfatal MIs were considered; in the second, the fatal MIs were in the cohort and included as endpoints.

All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).

Results {#Sec6}
=======

Participant characteristics {#Sec7}
---------------------------

Baseline characteristics of all participants at entry to TECOS are listed in Table [1](#Tab1){ref-type="table"} according to whether or not they had experienced an MI. Those with, compared without, an MI were more likely to be male (77.9% vs. 70.4%, P \< 0.0001), to have prior coronary artery disease (89.4% vs. 73.4%, P \< 0.0001), prior MI (57.8% vs. 42.0%, P \< 0.0001) or prior hHF (21.4% vs. 17.9%, P = 0.024); and to be treated less commonly with metformin (75.5% *vs.* 81.8%, P \< 0.0001) and more commonly with insulin (33.5% vs. 22.8%, P \< 0.0001).Table 1Baseline characteristics of TECOS participants who did not have a within-trial nonfatal myocardial infarction (MI), and for those participants with a nonfatal MI, split by sitagliptin or placebo treatmentCharacteristicPatients without a nonfatal MI during the trial randomized to sitagliptin or placebo\
N = 14,055Patients with a nonfatal MI during the trial*P*-value\*Sitagliptin\
N = 289Placebo\
N = 302Age at randomization (years)^a^65.0 (60.0, 71.0)67.0 (62.0, 74.0)66.0 (60.0, 72.0)0.1414Female4161 (29.6%)56 (19.4%)75 (24.8%)0.1103Hispanic or Latino1754 (12.5%)17 (5.9%)22 (7.3%)0.4924Race0.4603 White9472 (67.4%)235 (81.3%)234 (77.5%) Black422 (3.0%)10 (3.5%)14 (4.6%) Asian3184 (22.7%)38 (13.1%)42 (13.9%) Other977 (7.0%)6 (2.1%)12 (4.0%)Region0.5023 Latin America1445 (10.3%)10 (3.5%)11 (3.6%) Asia Pacific and other4377 (31.1%)98 (33.9%)84 (27.8%) Western Europe1977 (14.1%)48 (16.6%)50 (16.6%) Eastern Europe3822 (27.2%)63 (21.8%)68 (22.5%) North America2434 (17.3%)70 (24.2%)89 (29.5%)Duration^b^ of type 2 diabetes (years)10.0 (5.0, 16.0)11.0 (6.0, 18.0)11.0 (6.0, 16.0)0.3233Diabetes therapy at baseline (alone or in combination) Sulfonylurea6394 (45.5%)110 (38.1%)125 (41.4%)0.4085 Metformin11,501 (81.8%)212 (73.4%)235 (77.8%)0.2069 Thiazolidinedione376 (2.7%)9 (3.1%)9 (3.0%)0.9245 Insulin3208 (22.8%)98 (33.9%)98 (32.5%)0.7063Preexisting vascular disease13,975 (99.4%)288 (99.7%)302 (100.0%)0.4890Coronary artery disease10,312 (73.4%)261 (90.3%)269 (89.1%)0.6208Cerebrovascular disease3445 (24.5%)72 (24.9%)65 (21.5%)0.3289Peripheral arterial disease2348 (16.7%)40 (13.8%)42 (13.9%)0.9814Prior MI5899 (42.0%)171 (59.2%)170 (56.3%)0.4790Prior congestive heart failure2511 (17.9%)62 (21.5%)61 (20.2%)0.7072Previous atrial fibrillation/flutter1086 (7.7%)32 (11.1%)45 (14.9%)0.1670NYHA classification0.3241 1510 (20.3%)16 (25.8%)8 (13.1%) 21256 (50.0%)24 (38.7%)30 (49.2%) 3339 (13.5%)6 (9.7%)10 (16.4%) 411 (0.4%)1 (1.6%)1 (1.6%) Not available395 (15.7%)15 (24.2%)12 (19.7%)Qualifying HbA1c (mmol/mol)55.2 (50.8, 60.7)56.1 (51.0, 61.7)55.2 (51.9, 59.6)0.3239Qualifying HbA1c (%)7.2 (6.8, 7.7)7.3 (6.8, 7.8)7.2 (6.9, 7.6)0.3239eGFR (mL/min/1.73 m^2^)73.0 (60.0, 88.0)68.5 (55.0, 84.0)69.0 (56.0, 88.0)0.2918Urine albumin creatinine ratio (g/mol creatinine)10.6 (3.5, 35.0)12.2 (5.3, 52.7)13.8 (5.3, 43.9)0.9026Heart rate (bpm)72.0 (65.0, 79.0)70.0 (62.0, 78.0)71.0 (62.0, 80.0)0.0595Body mass index (kg/m^2^)29.5 (26.3, 33.2)29.8 (26.6, 33.5)30.4 (27.2, 34.3)0.1480Weight (kg)83.0 (71.0, 96.0)85.0 (75.0, 98.0)88.5 (75.0, 100.0)0.1517Height (cm)168.0 (160.0, 174.2)169.4 (163.2, 175.3)170.0 (162.6, 176.0)0.5036Cigarette smoking status0.9049 Current1589 (11.3%)44 (15.2%)43 (14.2%) Former5575 (39.7%)129 (44.6%)133 (44.0%) Never6891 (49.0%)116 (40.1%)126 (41.7%)Systolic blood pressure (mmHg)133.0 (124.0, 145.0)136.0 (124.0, 146.0)135.0 (124.0, 148.0)0.9803Diastolic blood pressure (mmHg)79.0 (70.0, 84.0)77.0 (68.0, 82.0)76.0 (68.0, 85.0)0.3050LDL-C84.0 (65.0, 109.0)81.0 (63.0, 99.6)82.1 (65.6, 108.1)0.4128Medications taken at time of randomization Statins11,213 (79.8%)238 (82.4%)248 (82.1%)0.9408 ACE inhibitors or angiotensin receptor blockers11,040 (78.5%)238 (82.4%)255 (84.4%)0.4959 Diuretics5727 (40.7%)127 (43.9%)150 (49.7%)0.1633 Calcium channel blockers4730 (33.7%)104 (36.0%)118 (39.1%)0.4386 Beta blockers8876 (63.2%)210 (72.7%)221 (73.2%)0.8881 Aspirin11,027 (78.5%)244 (84.4%)235 (77.8%)0.0403Data shown are median (interquartile range) or N (%)*ACE* angiotensin-converting enzyme, *eGFR* estimated glomerular filtration rate, *HbA1c* glycated hemoglobin, *LDL-C* low-density lipoprotein cholesterol, *NYHA* New York Heart Association, *TECOS* Trial Evaluating Cardiovascular Outcomes with Sitagliptin\**P*-value is for placebo vs sitagliptin in patients with a nonfatal MI^a^Age is missing among patients enrolled in Lithuania because the entire birth date including year was not available^b^Duration = (year of randomization − year of diagnosis) + 1

Fatal and nonfatal MI {#Sec8}
---------------------

A total of 616 (4.2%) of the 14,671 TECOS participants had a within-trial fatal or nonfatal MI (300 \[49%\] randomized to sitagliptin and 316 \[51%\] to placebo), with no significant difference in the time to first event by randomized therapy (HR 0.95, 95% CI 0.81--1.11, P = 0.49) as reported previously \[[@CR7]\]. Outcome information was missing for one participant for hHF and for two other participants for atrial fibrillation and stroke, limiting the number of participants who could be analyzed for these outcomes to 615 and 614, respectively. Twenty-five of these first MI events were fatal, 11 in the sitagliptin group and 14 in the placebo group, leaving 289 and 302 participants respectively with nonfatal MIs. Of the 591 participants who had a within-trial nonfatal MI, 87 (15%) died subsequently (66 \[11%\] classified as CV death), 57 (10%) experienced hHF, 109 (18%) had a second MI, 20 (3%) had a stroke, and 37 (6%) had incident atrial fibrillation.

CV events after nonfatal MI {#Sec9}
---------------------------

The composite outcome of CV death or hHF following a nonfatal MI occurred in 58 of 289 sitagliptin group participants (20.1%; 13.9 events per 100 person-years) and in 50 of 302 placebo group participants (16.6%; 11.7 per 100 person-years), with no significant difference between groups (HR 1.21, 95% CI 0.83--1.77, P = 0.32; adjusted HR 1.23, 95% CI 0.83--1.82, P = 0.31) (Fig. [1](#Fig1){ref-type="fig"}a and Table [2](#Tab2){ref-type="table"}). Similar results were seen for the individual outcomes of CV death, hHF, incident heart failure, recurrent MI, and all-cause death, and for the extended composite (CV death, hHF, incident heart failure, recurrent MI, stroke, or incident atrial fibrillation), with no significant differences also seen after adjustment for potential confounders (Table [2](#Tab2){ref-type="table"}). Results were also similar when fatal MI was included in the cohort of interest (Additional file [1](#MOESM1){ref-type="media"}: Table S2, Figure S1).Fig. 1Unadjusted event curves by randomized assignment to sitagliptin or placebo (Kaplan--Meier plots) for the composite outcome of cardiovascular (CV) death or heart failure hospitalization (hHF) (**a**) and for CV death (**b**), both occurring after the first within-trial nonfatal myocardial infarction (MI) (defining day 0 on the x-axis). Intention-to-treat analysis Table 2Cardiovascular outcomes occurring after a first within-trial non-fatal myocardial infarction in those randomized previously to sitagliptin or placebo treatment (intention-to-treat analysis)Sitagliptin\
n = 289Placebo\
n = 302Unadjusted hazard ratio (95% CI)P-valueAdjusted hazard ratio (95% CI)P-valueNo. (%)Events per 100 patient-yearsNo. (%)Events per 100 patient-yearsCardiovascular death or hospitalization for heart failure58 (20.1)13.950 (16.6)11.71.21 (0.83--1.77)0.321.23 (0.83--1.82)0.31Cardiovascular death34 (11.8)7.632 (10.6)7.11.11 (0.68--1.81)0.671.12 (0.67--1.86)0.67Hospitalization for heart failure31 (10.7)7.526 (8.6)6.11.26 (0.75--2.12)0.391.40 (0.80--2.42)0.23New onset heart failure19 (6.6)4.317 (5.6)3.81.25 (0.64--2.44)0.511.49 (0.72--3.09)0.28Cardiovascular death, hospital admission for heart failure, new heart failure, acute myocardial infarction, stroke or new-onset atrial fibrillation108 (37.4)33.0100 (33.1)28.41.16 (0.89--1.53)0.271.21 (0.91--1.60)0.20Further acute myocardial infarction54 (18.7)7.455 (18.2)7.11.01 (0.69--1.48)0.950.99 (0.67--1.46)0.95All-cause death50 (17.3)11.037 (12.3)8.11.40 (0.92--2.15)0.121.41 (0.90--2.21)0.13

On-treatment sensitivity analyses {#Sec10}
---------------------------------

At the time of the first nonfatal MI, 249 (42%) participants were taking a DPP-4i and 341 (58%) were not. There was no significant difference in the composite outcome of CV death or hHF for those treated or not treated with a DPP-4i (Fig. [2](#Fig2){ref-type="fig"}a and Table [3](#Tab3){ref-type="table"}) for either unadjusted analyses (HR 0.91, 95% CI 0.62--1.34, P = 0.63) or adjusted analyses (HR 0.95, 95% CI 0.64--1.43, P = 0.82). All results were consistent with those for the intention-to-treat analyses, although CV deaths were numerically less in those treated with a DPP4i (HR 0.75). Results were also consistent when first fatal MI was included in the analysis (Additional file [1](#MOESM1){ref-type="media"}: Table S3, Figure S2).Fig. 2Unadjusted event curves by dipeptidyl peptidase-4 inhibitor (DPP-4i) treatment received versus no treatment (Kaplan--Meier plots) for the composite outcome of cardiovascular (CV) death or heart failure hospitalization (hHF) (**a**) and for CV death (**b**), both occurring after the first within-trial nonfatal myocardial infarction (MI) (defining day 0 on the x-axis). On-treatment sensitivity analysis Table 3Cardiovascular outcomes occurring after a first within-trial nonfatal myocardial infarction in those pretreated or not pretreated with a dipeptidyl peptidase-4 inhibitor (DPP-4i) (on-treatment sensitivity analysis)DPP-4i treated\
n = 249Not DPP-4i treated\
n = 341Unadjusted hazard ratio (95% CI)P-valueAdjusted hazard ratio (95% CI)P-valueNo. (%)Events per 100 patient-yearsNo. (%)Events per 100 patient-yearsCardiovascular death or hospitalization for heart failure45 (18.1)11.962 (18.2)13.30.91 (0.62--1.34)0.630.95 (0.64--1.43)0.82Cardiovascular death25 (10.0)6.240 (11.7)8.10.78 (0.47--1.29)0.340.75 (0.44--1.26)0.27Hospitalization for heart failure27 (10.8)7.230 (8.8)6.41.15 (0.68--1.94)0.601.34 (0.77--2.33)0.31New onset heart failure16 (6.4)4.020 (5.9)4.11.05 (0.54--2.05)0.881.34 (0.64--2.79)0.44Cardiovascular death, hospital admission for heart failure, new heart failure, acute myocardial infarction, stroke or new-onset atrial fibrillation87 (34.9)28.8120 (35.2)31.80.92 (0.70--1.22)0.560.95 (0.71--1.27)0.72Further acute myocardial infarction46 (18.5)7.263 (18.5)7.30.97 (0.66--1.42)0.890.99 (0.67--1.46)0.95All-cause death37 (14.9)8.949 (14.4)9.90.94 (0.61--1.44)0.770.91 (0.58--1.43)0.68

Discussion {#Sec11}
==========

Although preclinical data provided theoretical support \[[@CR19]--[@CR22]\], these post hoc TECOS analyses found no evidence that treatment with sitagliptin, compared with placebo, given prior to a first within-trial nonfatal MI had any impact on subsequent CV outcomes. Similar results were obtained when previous use of any DPP-4i was examined, and in sensitivity analyses that included fatal as well as nonfatal MIs.

Possible explanations for the discordance between human and animal observations include the following: (1) all TECOS participants had established ASCVD versus the lack of disease in experimental animals; (2) our study had only modest statistical power with just 123 composite outcome events analyzed; (3) experimentally induced MI is typically the consequence of total occlusion of a large coronary vessel, leading to a rather large area of myocardial necrosis, associated with adverse clinical consequences and significant mortality in the animal models---in contrast, spontaneous acute MI in humans is more variable in terms of the size of the relevant coronary vessel and the corresponding size of the subtended myocardium, whether complete occlusion of the coronary occurs, and marked variability in the timing from MI onset to clinical presentation, all of which translates into highly variable sizes of the area at risk, i.e. receiving blood supply from the infarct-related vessel, and of the necrotic area \[[@CR25], [@CR26]\]; (4) the doses of sitagliptin used in the animal studies are roughly twofold or more higher \[[@CR19]--[@CR22]\]; and (5) not all TECOS participants may have been adherent with respect to their study medication, and the GLP-1 receptor agonism augmented by DPP-4is does not have the same CV consequences in humans that has been demonstrated in animal studies \[[@CR15]--[@CR22]\]. Our results, however, are supported by negative results reported from a similar analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial examining effects of liraglutide versus placebo pretreatment on CV events following MI occurring during the trial \[[@CR30]\].

Controversy persists regarding the effects of DPP-4is on heart failure risk, originating from the observation of an increased risk of hHF with saxagliptin in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI) 53 trial \[[@CR31]\] with a similar non-significant trend in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial with alogliptin \[[@CR32]\], but no hHF signal observed with sitagliptin \[[@CR27]\] or linagliptin \[[@CR33]\]. On the other hand, results from observational studies have yielded counter-observations, reporting lower hHF risk associated with DPP-4i use compared with GLP-1 receptor agonists, with no significant difference in patients with a history of heart failure \[[@CR34]\], and no difference in the risk of hHF when DPP-4i use was compared with sulfonylurea \[[@CR35]\]. If DPP-4i treatment increases heart failure risk, the mechanism remains elusive. By echocardiographic criteria, a trend toward worsening diastolic ventricular function was slowed with sitagliptin treatment \[[@CR36]\]. As a potential reason for a heterogeneity in effects between different DPP-4is, a suppression of renal sodium-hydrogen exchanger 3 activity with agents that are excreted in the urine (sitagliptin, alogliptin and linagliptin) has been proposed to protect from DPP-4i--induced heart failure \[[@CR37]\]. In the present analysis, in accord with prior results of no heart failure effects of sitagliptin in the overall TECOS cohort, no association between sitagliptin and heart failure events was observed post-MI \[[@CR7], [@CR8], [@CR27]\]. Thus, sitagliptin seems to be safe in patients during and after acute MI. Whether this applies to other DPP-4is needs to be studied in dedicated analyses from the respective CV outcomes trials \[[@CR5], [@CR6], [@CR10]\]. Along these lines, a meta-analysis of other CV outcomes trials with DPP-4is (e.g. SAVOR TIMI-53 \[[@CR5]\], EXAMINE \[[@CR6]\], CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin \[CARMELINA\] \[[@CR9], [@CR10]\], and CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes \[CAROLINA\] \[[@CR38]\]) could provide further clarification.

Limitations of the present analyses include the non-randomized selection of the subset with MI for analysis \[[@CR7], [@CR8]\]. In addition, incomplete adherence to randomized treatment that could have occurred selectively post-MI could further confound comparative analyses. These analyses had limited power given the relatively few patients with MI with subsequent outcomes of interest. However, this data set is larger than most available with an ability to explore such associations.

Conclusions {#Sec12}
===========

In summary, these post hoc analyses of data from TECOS participants who had type 2 diabetes and ASCVD do not support the preclinically derived hypothesis that DPP-4i treatment prior to an MI can reduce the subsequent risk of CV death or hHF.
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**Additional file 1: Table S1.** Factors included in adjustment models for each clinical endpoint. **Table S2.** Cardiovascular outcomes occurring after a first within-trial fatal or nonfatal myocardial infarction in those randomized previously to sitagliptin or placebo treatment (intention-to-treat analysis). **Table S3.** Cardiovascular outcomes occurring after a first within-trial fatal or nonfatal myocardial infarction in those pretreated or not pretreated with a DPP-4i (on-treatment sensitivity analysis). **Figure S1.** Unadjusted event curves by randomized assignment to sitagliptin or placebo (Kaplan--Meier plots) for the composite outcome of cardiovascular death or heart failure hospitalization (A) and for cardiovascular death (B), both occurring after the first within-trial myocardial infarction during the TECOS trial (defining day 0 on the x-axis). Intention-to-treat analysis. **Figure S2.** Unadjusted event curves by treatment received, DPP-4i versus no DPP-4i, Kaplan-Meier plots for the composite outcome of cardiovascular death or heart failure hospitalization (A), and for cardiovascular death (B), both occurring after the first nonfatal within-trial myocardial infarction (defining day 0 on the x-axis). On-treatment sensitivity analysis.

ASCVD

:   atherosclerotic cardiovascular disease

CV

:   cardiovascular

DPP-4is

:   dipeptidyl peptidase-4 inhibitors

hHF

:   hospitalization for heart failure

MI

:   myocardial infarction

TECOS

:   Trial Evaluating Cardiovascular Outcomes with Sitagliptin

**Publisher\'s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Michael A. Nauck and Darren K. McGuire contributed equally to this article

Supplementary information
=========================

**Supplementary information** accompanies this paper at 10.1186/s12933-019-0921-2.

The authors acknowledge John Schibler for his help in generating graphics and formatting tables of this study. The authors thank Peter Hoffmann for excellent editorial support. RRH is an NIHR Senior Investigator.

Previous presentation {#FPar1}
=====================

Poster at the 2017 Annual Meeting of the European Association for the Study of Diabetes.

MAN, KSP, and RRH designed the study. YL and KSP performed the analyses. MAN wrote the initial draft of the manuscript, and all authors were involved in revising it and in deciding to submit the final version for publication. All authors read and approved the final manuscript.

The TECOS trial was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. The study was designed and run independently by the Duke Clinical Research Institute (DCRI) and the University of Oxford Diabetes Trials Unit (DTU) in an academic collaboration with the sponsor. All analyses were performed by DCRI and DTU independent of the sponsor. The authors are solely responsible for the design and conduct of this study, all analyses, the drafting and editing of the paper, and its final contents. All authors agreed to submit the report for publication; the funder had no role in this decision.

Requests to access the data for this study from qualified researchers trained in human subject confidentiality protocols may be submitted at dcri.org/data-sharing.

The trial was designed and overseen by a steering committee, and an independent data and safety monitoring committee performed regular safety surveillance. All patients provided written informed consent. Institutional review board approval was required at all participating institutions.

Not applicable.

MAN has been a member of advisory boards or consulted for AstraZeneca (moderate), Boehringer Ingelheim (moderate), Eli Lilly & Co. (significant), Fractyl (moderate), GlaxoSmithKline (moderate), Intarcia (moderate), Menarini/Berlin Chemie (moderate), Merck, Sharp & Dohme (significant), and NovoNordisk (significant). His institution has received grant support from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., GlaxoSmithKline, Intarcia, Menarini/Berlin-Chemie, Merck, Sharp & Dohme, Novartis Pharma, and Novo Nordisk A/S. He has also served on the speakers' bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., GlaxoSmithKline, Menarini/Berlin Chemie (all moderate), Merck, Sharp & Dohme, and Novo Nordisk A/S (both significant). DKM has provided clinical trial leadership for AstraZeneca, Sanofi Aventis, Janssen, Boehringer Ingelheim, Merck & Co, Pfizer, Lilly US, Novo Nordisk, Lexicon, Eisai, GlaxoSmithKline, and Esperion, and consultancy for AstraZeneca, Sanofi Aventis, Lilly US, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Applied Therapeutics, Afimmune and Metavant. KSP has no disclosures. YL has received grants from Merck, Janssen Research & Development, AstraZeneca, GlaxoSmithKline, and Bayer HealthCare AG. TES reports personal fees from several companies (incl. Amgen, AstraZeneca, Merck, NovoNordisk, Pfizer, Orion, Bayer, Boehringer-Ingelheim) and owns a minor amount of stock in OrionPharma. AR has no disclosures. TD has no disclosures. EDP has received grants from Janssen, Merck, Sanofi, AstraZeneca, Genentech, and Amgen, and has consulting associations with Janssen, Bayer, Merck, and Sanofi. HDW reports research grants from GlaxoSmithKline, Sanofi-Aventis, Eli Lilly and Company, National Institute of Health, Merck Sharp & Dohme, George Institute, Omthera Pharmaceuticals, Pfizer New Zealand, Intarcia Therapeutics Inc., Elsai Inc., Daiichi-Sankyo, DalCor Pharmaceuticals; Advisory board/lecture fees from AstraZeneca, Acetelion, Sirte and he is a Steering Board member for Luitpold Pharmaceuticals Ltd and CSL Behring LLC. RS has no disclosures. RRH reports receiving grants from AstraZeneca during the conduct of the study and grants and personal fees from Bayer, Boehringer Ingelheim and Merck Sharp&Dohme Corp., a subsidiary of Merck & Co., Inc.; personal fees from Novartis, Amgen, and Servier; and financial support from Elcelyx, GlaxoSmithKline, Janssen, and Takeda outside the submitted work.
